对心血管疾病的个性化方法:对FDA批准的干预措施和临床药物遗传学的洞察
Ramin Raoufinia1,2, Hamid Reza Rahimi2, Mahla Abbaszadeh3
1Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Current pharmaceutical design
|May 13, 2024
概括
个性化医疗提供了一种有前途的方法来治疗心血管疾病 (CVD),通过为个体量身定制治疗方法. 该战略旨在更早地检测和干预,改善结果并减少心脏病的负担.
科学领域:
- 心脏病学 心脏病学
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病 (CVD) 构成了全球重大健康负担,其特点是患病率和死亡率高.
- 目前的心血管疾病管理往往涉及疾病进展后的症状治疗,强调需要主动策略.
研究的目的:
- 在心血管疾病的背景下提供个性化医学的概述.
- 强调FDA批准的干预措施,并探索它们在定制治疗中的作用.
- 讨论个性化心血管医学的好处,挑战和未来发展轨迹.
主要方法:
- 关于个性化医学和心血管疾病的当前文献的综述.
- 对FDA批准的针对心血管疾病的个性化干预措施的分析.
- 探索早期检测和有针对性的治疗策略的进展.
主要成果:
- 个性化医疗证明了通过将干预措施定制到个体患者资料来改善心血管健康结果的潜力.
- 美国食品和药物管理局批准的个性化疗法正在成为管理特定心血管疾病的关键组成部分.
- 早期检测和主动干预对于减轻心血管疾病的影响至关重要.
结论:
- 个性化医疗是一种心血管保健的变革性方法,将重点从一般化转向个性化治疗策略.
- 在个性化医学的持续研究和开发对于减少心血管疾病的全球负担至关重要.
- 整合个性化的方法有望提高心血管疾病预防和管理的有效性.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
57
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
57
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Model Approaches for Pharmacokinetic Data: Physiological Models
42
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
42
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
60
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
60


